+91-8668442535

Neurological Diseases Treatment Market By Indication (Epilepsy, Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Cerebrovascular Disease, Others) By Drug (Class, Cholinesterase Inhibitors, NMDA Receptor Antagonists, Antiepileptic, Antipsychotic and Antidepressant, Others) By Route of Administration (Oral, Parenteral, Others) By End Users ( Hospitals, Specialty Clinics, Homecare, Others) By Distribution Channel - Growth, Future Prospects And Competitive Analysis, 2016 - 2028

How is the prominence of the neurological disease treatment market?

In the long term, it is anticipated that the market for treating uncommon neurodegenerative diseases would profit from the development in medical tourism and investments in upgrading healthcare facilities throughout the emerging nations of Asia Pacific. In addition, medical technology advancements for detecting and treating various illnesses will support long-term growth. Furthermore, the growing elderly population and the rising frequency of neurological illnesses including Parkinson's, Alzheimer's, multiple sclerosis, and others are expected to drive the global market for central nervous system treatments.

neurological-diseases-treatment-market

What is the Market Size of Neurological disease treatment in terms of value?

Global Neurological Disease Treatment Market is projected to increase at a significant CAGR of XX in the coming years. In 2021, the Global Neurological Disease Treatment Market was valued at USD XX Million and is projected to reach USD XX million by 2028. The demand for neurological disease treatment is projected to increase substantially in the coming years. It is presumed to generate revenue opportunities for the key industry players worth USD XX million during the forecast period between 2022 and 2028.

Interesting Facts about the Neurological disease treatment Industry

  • An examination of the market for treating rare neurological diseases analyses the major variables influencing current trends and market size, forecast, and technical developments.
  • The anticipated period will see an absolute monetary potential of more than $5 billion from healthcare spending on Alzheimer's disease therapy.
  • Over the projected period, the retail pharmacy and drug store business is anticipated to grow while maintaining high client satisfaction standards.
  • North America controls 40% of the global market for rare neurological disease treatments in terms of revenue.
  • Various treatments used to treat various neurological illnesses are discussed, the innovative pipeline, the patent expiration of blockbuster drugs, and new medication approvals.
  • Companies in the neurological disorder medicines industry are implementing new therapeutic methods for treating Parkinson's disease.

Who are the Top 10 players/companies in the neurological disease treatment market in terms of value?

The key players in the global neurological disease treatment market in terms of value include Merck KGaA (Germany), Eisai Co., Ltd. (Japan), AstraZeneca (U.K.), Sanofi (France), Novartis AG (Switzerland), Abbott (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Teva Pharmaceutical Industries Ltd. (Ireland), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), WOCKHARDT (Mumbai), Novo Nordisk A/S (Denmark), Glenmark Pharmaceuticals Limited (India), Cipla Inc. (U.S.), Bausch Health Companies Inc. (Canada), Otsuka America Pharmaceutical, Inc. (US), Johnson & Johnson Private Limited (U.S.), Takeda Pharmaceutical Company Limited (Japan), Sumitomo Corporation (Japan), Biocon (India). In September 2021 Four psychiatric and neurology chemicals, including ulotaront, are the subject of a licensing deal between Otsuka and Sumitomo Dainippon Pharma. As per the agreement, Sunovion and Otsuka will equally divide the expenses and income from clinical studies, regulatory filings, and commercialization in each of these countries and regions. After further conversations between Sumitomo Dainippon Pharma Group and Otsuka, additional ulotaront indications will be discovered. The U.S. FDA gave Johnson & Johnson permission to introduce Ponvory as a daily oral medication for the treatment of multiple sclerosis.

Who are the Top 10 Countries in the Neurological Disease Treatment Market?

In the global neurological disease treatment market, the major countries are China, India, the U.S., Canada, the U.K., Germany, France, Russia, Belgium, Netherlands, and Norway. For each regional market, a country-specific assessment of the demand for treatments for rare neurological diseases has been provided, along with estimates of market size and forecast price points, price indices, and the effects of significant regional and national dynamics. These estimates were compiled using quotes from many suppliers, manufacturers, experts, and manufacturers of treatments for rare neurological diseases. On all of the regional markets that were included in the research, growth estimates were also provided. In addition, the research provides answers to questions about potential market trends, development prospects, and other possibilities.

Which is the major drug class in the Neurological disease treatment Market?

The major drug class of neurological disease treatment includes Cholinesterase Inhibitors, NMDA Receptor Antagonists, Anticholinergic, Antiepileptic, Antipsychotic and Antidepressant, and others. Together, anticholinergic and antiepileptic medications accounted for around 42% of the market. Rising neurological illness prevalence, ongoing advancements in diagnostic technology, and increased knowledge of early disease detection due to awareness programs run by governmental or non-governmental organizations are the main reasons fueling the growth of these two market sectors. The market launch of effective pharmaceuticals in the near future, however, due to a robust drug pipeline, is anticipated to alter the market share of conventional drug therapies and further accelerate this market's expansion.

What are the Major Driving Factors for the Neurological disease treatment Market?

The growing cost of healthcare, which helps to improve its infrastructure, is a crucial element affecting the market's growth rate for dermatitis. Different government organizations' efforts to strengthen the healthcare infrastructure by boosting financing will further impact the market dynamics. The market is also expanding since more new medications are being developed. This would present advantageous chances for the expansion of the market. Neurological disorders and brain traumas are among the leading causes of death in the globe. As a result, scientists are looking for ways to develop novel drugs that, by modifying glucose metabolism, might enhance the treatment of neurological illnesses.

What are the Major Restraints for the Neurological disease treatment Market?

The key restraint of the global neurological disease treatment market, which is projected to hamper the market growth, include the high cost of research and development operations, which would impede the market's rate of expansion. In addition, the market for medications for neurological disorders will face difficulties due to the absence of healthcare infrastructure in developing countries and a shortage of qualified personnel. Furthermore, during the projection period, product recalls, and stringent government restrictions would serve as restraints and further hinder the market's development pace.

Which Region Dominated the World Neurological Disease Treatment Market?

In terms of market share and revenue, North America now dominates the market for medications for neurological disorders, and this dominance is expected to grow over the projected period. This is because neurological disorders are very common in this area, and growing healthcare costs will further accelerate market expansion. The market's growth rate in this area will also be boosted by the expanding presence of major important players and the rise in the number of FDA-approved pharmaceuticals. Because there are so many generic manufacturers in Asia-Pacific, the area is predicted to increase between 2022 and 2029. Additionally, expanding the healthcare sector's infrastructure and growing government efforts will accelerate the market's expansion in this area. The rising occurrence of such uncommon neurological illnesses in the region has been one of the main drivers of the North American market's expansion. Around 200,000 people in the US alone are affected by uncommon neurological disorders, according to research from the Center for Rare Neurological Disease Research. Additionally, it is anticipated that rising healthcare spending and the availability of a developed and well-established healthcare infrastructure would support the growth of the North American area.

Segmentation of Global Neurological Disease Treatment Market-

Global Neurological Disease Treatment Market – By Indication

  • Epilepsy
  • Alzheimer’s Disease
  • Parkinson’s Disease
  • Multiple Sclerosis
  • Cerebrovascular Disease
  • Others

 Global Neurological Disease Treatment Market – By Drug Class

  • Cholinesterase Inhibitors
  • NMDA Receptor Antagonists
  • Antiepileptic
  • Antipsychotic and Antidepressant
  • Others

Global Neurological Disease Treatment Market – By Route of Administration

  • Oral
  • Parenteral
  • Others

Global Neurological Disease Treatment Market – By End Users

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

Global Neurological Disease Treatment Market – By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

Frequently asked questions about the global Neurological Disease Treatment industry

Asia-Pacific is expected to grow during the forecast period of 2022-2029 due to the high presence of generic manufacturers in this region. Additionally, expanding the healthcare sector's infrastructure and growing government efforts will accelerate the market's expansion in this area.

The growing cost of healthcare contributes to the development of the market for dermatitis and has a significant impact on its growth rate. Different government organizations' efforts to strengthen the healthcare infrastructure by boosting financing will further impact the market dynamics.

Together, epilepsy, Alzheimer's disease, and Parkinson's disease accounted for of the market share because of these diseases' rising prevalence, the development of novel diagnostic tools for neurological conditions, and the expansion of awareness campaigns run by both governmental and non-governmental organizations.

Based on the distribution channel, the hospital pharmacy category was able to grasp the global increasing preference for hospital-based therapy and more substantial sales revenue.

Neurological Disease Treatment Market Scope

Report Attribute Details
Market Value in 2021 USD XX Million
Market Value in 2028 USD XX million
CAGR XX %
Benchmarking Year 2021
Past data 2016 – 2021
Forecast period 2022 – 2028
Choose License Type
Trusted By
Godaddy
Published Date:  Jul 2022
Category:  Pharmaceuticals
Report ID:   58724
Report Format:   PDF
Pages:   190
Rating:    4.9 (60)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
+91-8668442535
24/7 Research Support